Premium
CAMIDANLUMAB TESIRINE EFFICACY AND SAFETY IN AN OPEN‐LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS (PTS) WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL)
Author(s) -
Zinzani P. L.,
CarloStella C.,
Hamadani M.,
Herrera A. F.,
Ansell S. M.,
Radford J.,
Maddocks K.,
Kline J.,
Savage K. J.,
Bartlett N. L.,
Caimi P. F.,
Negievich Y.,
Cruz H. G.,
Wang L.,
Wuerthner J.,
Collins G. P.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.75_2879
Subject(s) - medicine , brentuximab vedotin , refractory (planetary science) , adverse effect , phases of clinical research , clinical trial , oncology , surgery , gastroenterology , lymphoma , hodgkin lymphoma , physics , astrobiology